Facilitated By

San Antonio Medical Foundation

A PHASE II MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED DOSE TITRATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACODYNAMIC EFFECTS OF CK-2017357 IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS)

UT Health San Antonio

The UT Health San Antonio, with missions of teaching, research and healing, is one of the country’s leading health sciences universities.

Principal Investigator(s)
Jackson,Carlayne E
Funded by
CYTOKINETICS
Research Start Date
Status
Inactive
Clinical Care
Drug Discovery
Neuroscience